/

SLDB

Solid Biosciences Inc.Closed

5.82−0.89 −13.26%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 5.93 +1.89%

Open

6.65

Prev close

6.71

Day range

5.716.65

52-week range

3.7911.45

Volume

2.87M2.67×

Mkt cap

624.05M

P/E ttm

—

Fwd P/E

-3.41

EPS ttm

-1.89

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−49.17%

Price Chart

Yahoo Finance · delayed

SLDBOct 12, 2026O 6.85H 6.93L 6.69C 6.71−0.16 (−2.33%)Vol 601.30K

SMA 508.61
SMA 2007.63

1Y change +12.58% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SLDB Solid Biosciences Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.96%
1 month: −22.87%
3 months: −30.97%
6 months: −20.02%
Year to date: +18.97%
1 year: +12.58%

Valuation & ownership

Market cap: 624.05M
Enterprise value: 266.53M
P/E (ttm): —
Forward P/E: -3.41
PEG ratio: —
Price / book: 1.64
Price / sales (ttm): —
EV / EBITDA: -1.27
EPS (ttm): -1.89
EPS (forward): -1.70
Beta (5y monthly): 2.47
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 107.23M
Float: 64.81M
Short % of float: 13.49%
Short ratio (days): 10.04
Held by insiders: 0.68%
Held by institutions: 107.59%
Avg volume (3m): 1.07M
50-day average: 8.61
200-day average: 7.63
52-week change: +12.58%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 30.4
vs 50-day SMA: −22.06%
vs 200-day SMA: −12.00%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.24%
Realised vol (20d, ann.): 57.5%
From 52-week high: −41.40%
From 52-week low: +77.04%

ANR

Analyst Consensus

13 analysts

Consensus

Strong buy

1.38 on a 1 (strong buy) – 5 (sell) scale

Mean target

18.62

+219.85% implied

Low 11.00Median 18.00High 26.00

Recommendation trend

Now13 / 0 / 0
1m ago13 / 0 / 0

DES

About Solid Biosciences Inc.

Yahoo Finance profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 121
Headquarters: Charlestown, MA, United States
Website: solidbio.com
Officers: Mr. Ian F. Smith A.C.A., C.P.A.

SEAS

Seasonality · SLDB

2018–2026 · monthly returns

Strongest month Dec +25.03%Weakest month Mar −13.33%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	14.5	-3.9	15.9	0.8	1.1	36.1	-19.3	18.9	-24.5	-19.5			+3.2%
2025	-20.5	75.8	-33.8	-10.5	-3.0	51.7	40.5	-19.9	12.6	-12.6	0.7	3.9	+41.0%
2024	12.2	36.3	41.9	-33.4	-6.9	-31.4	57.3	0.1	-21.9	-20.8	3.3	-29.8	−34.9%
2023	40.9	-25.9	-15.7	3.0	26.6	-15.2	-17.7	-16.2	-30.2	-11.5	26.5	117.7	+14.1%
2022	-30.3	-33.2	47.2	-53.3	1.8	8.1	9.6	-5.2	-27.0	-8.5	4.5	-19.7	−79.5%
2021	-14.0	22.2	-30.6	-8.0	-25.3	-3.7	-23.8	-2.9	-11.8	-15.1	-13.8	0.0	−76.9%
2020	-24.7	-1.5	-27.6	-2.9	27.2	-0.7	-10.2	-9.1	-15.1	61.1	1.2	129.0	+70.3%
2019	-6.1	-57.5	-13.9	-1.3	-39.1	4.0	-0.3	41.0	28.0	6.9	-64.4	13.2	−83.4%
2018		13.2	-74.1	90.9	50.7	65.1	12.8	6.1	10.6	-32.2	-2.6	-14.0	+4.6%

INSD

Insider Activity · SLDB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 1, 2026	Smith Ian FDirector	—	3.4K	—
Jul 1, 2026	Smith Ian FDirector	—	3.4K	—
Apr 1, 2026	Smith Ian FDirector	—	3.4K	—
Feb 17, 2026	Tan KevinChief Financial Officer	Sale at price 5.82 per share.	5.4K	$31.47K
Feb 17, 2026	Hanrahan JessieOfficer	Sale at price 5.82 per share.	4.1K	$24.07K
Feb 17, 2026	Herzich PaulChief Technology Officer	Sale at price 5.82 per share.	3.6K	$21.06K
Feb 17, 2026	Brooks Gabriel M.D.Officer	Sale at price 5.92 per share.	89.5K	$529.64K
Feb 17, 2026	Howton David TyronneChief Operating Officer	Sale at price 5.82 per share.	7.5K	$43.49K
Feb 17, 2026	Cumbo AlexanderChief Executive Officer	Sale at price 5.82 per share.	16.6K	$96.92K
Feb 17, 2026	Ganot IlanDirector	Sale at price 5.82 per share.	2.7K	$15.48K
Feb 12, 2026	Howton David TyronneChief Operating Officer	—	14.7K	—
Feb 12, 2026	Cumbo AlexanderChief Executive Officer	—	30K	—
Feb 12, 2026	Ganot IlanDirector	—	4.9K	—
Feb 12, 2026	Tan KevinChief Financial Officer	—	10.6K	—
Feb 12, 2026	Hanrahan JessieOfficer	—	8.1K	—
Feb 12, 2026	Herzich PaulChief Technology Officer	—	7.2K	—
Feb 12, 2026	Brooks Gabriel M.D.Officer	—	10.9K	—
Feb 3, 2026	Tan KevinChief Financial Officer	Sale at price 6.44 per share.	14.8K	$95.23K
Feb 3, 2026	Hanrahan JessieOfficer	Sale at price 6.44 per share.	12.3K	$79.55K
Feb 3, 2026	Herzich PaulChief Technology Officer	Sale at price 6.44 per share.	10.9K	$70.25K

13F

Investors Holding SLDB

latest 13F filings of 29 followed managers

Investors holding SLDB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$820.2K	0.00%	82.10K	−34%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

SLDB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SLDB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Solid Biosciences Inc.

Seasonality · SLDB

Insider Activity · SLDB

Congress Trades · SLDB

Investors Holding SLDB

Investors Holding SLDB

Congress Trades · SLDB

Insider Activity · SLDB

Seasonality · SLDB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Solid Biosciences Inc.

Financial Snapshot

Earnings & Dividends

News